FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Vincent Brandenburg; Smeeta Sinha; Jose-Vicente Torregrosa; Lance Berman; Stephan Miller; Ana-Zeralda Canals; Daun Bahr; Preston Klassen; Pieter Joubert; Carolina Salcedo; Rekha Garg; Joan Perelló

doi:10.1093/ndt/gfy104.fo020

FO020A PHASE 2 OPEN-LABEL SINGLE-ARM STUDY TO ASSESS THE EFFECT OF SNF472 ON WOUND HEALING IN CALCIPHYLAXIS (CALCIFIC UREMIC ARTERIOLOPATHY) PATIENTS

Nephrology Dialysis Transplantation ◽

10.1093/ndt/gfy104.fo020 ◽

2018 ◽

Vol 33 (suppl_1) ◽

pp. i9-i9 ◽

Cited By ~ 2

Author(s):

Vincent Brandenburg ◽

Smeeta Sinha ◽

Jose-Vicente Torregrosa ◽

Lance Berman ◽

Stephan Miller ◽

...

Keyword(s):

Wound Healing ◽

Phase 2 ◽

Open Label ◽

Calcific Uremic Arteriolopathy

Download Full-text

Improvement in wound healing, pain, and quality of life after 12 weeks of SNF472 treatment: a phase 2 open-label study of patients with calciphylaxis

Journal of Nephrology ◽

10.1007/s40620-019-00631-0 ◽

2019 ◽

Vol 32 (5) ◽

pp. 811-821 ◽

Cited By ~ 9

Author(s):

Vincent M. Brandenburg ◽

Smeeta Sinha ◽

Jose-Vicente Torregrosa ◽

Rekha Garg ◽

Stephan Miller ◽

...

Keyword(s):

Quality Of Life ◽

Wound Healing ◽

Phase 2 ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Decision letter for "Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia"

10.1002/jbmr.4184/v1/decision1 ◽

2020 ◽

Keyword(s):

Interim Analysis ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label

Download Full-text

Review for "Interim Analysis of a Phase 2 Open‐Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor‐Induced Osteomalacia"

10.1002/jbmr.4184/v2/review2 ◽

2020 ◽

Keyword(s):

Interim Analysis ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label

Download Full-text

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.11 ◽

2017 ◽

Vol 1 ◽

pp. s12

Author(s):

Andrew Blauvelt ◽

Craig Leonardi ◽

Claus Zachariae ◽

Russel Burge ◽

Terri Ridenour ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Chronic Plaque Psoriasis ◽

Open Label ◽

Phase 2 Study ◽

Health Related

Abstract Not Available

Download Full-text

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Case Medical Research ◽

10.31525/ct1-nct04257929 ◽

2020 ◽

Author(s):

Keyword(s):

Prader Willi Syndrome ◽

Phase 2 ◽

Open Label ◽

Safety And Efficacy ◽

Phase 2 Study ◽

Open Label Extension

Download Full-text

Faculty Opinions recommendation of Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717797810.793153212 ◽

2012 ◽

Author(s):

Klaus Klaushofer

Keyword(s):

Bone Mineral Density ◽

Back Pain ◽

Bone Mineral ◽

Phase 2 ◽

Mineral Density ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Faculty Opinions recommendation of Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717954976.793462183 ◽

2012 ◽

Author(s):

Mark Faries

Keyword(s):

Advanced Melanoma ◽

Phase 2 ◽

Open Label ◽

Phase 2 Trial

Download Full-text

Faculty Opinions recommendation of Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718020296.793478787 ◽

2013 ◽

Author(s):

Arthur Kim

Keyword(s):

Hepatitis C ◽

Phase 2 ◽

Genotype 1 ◽

Hepatitis C Infection ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial ◽

Treatment Naïve ◽

Peginterferon Alfa ◽

Ns3 Protease

Download Full-text

Faculty Opinions recommendation of An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718028323.793480222 ◽

2013 ◽

Author(s):

Richard Riedel

Keyword(s):

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Phase 2 ◽

Efficacy And Safety ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase ◽

Metastatic Soft Tissue Sarcoma ◽

Previously Treated

Download Full-text

Faculty of 1000 evaluation for Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718052125.793484801 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Germ Cell ◽

Children And Adolescents ◽

Salvage Treatment ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Institution ◽

Open Label ◽

Phase 2 Study ◽

Deep Hyperthermia

Download Full-text